Samsung Bioepis - Articles and news items

Samsung Bioepis seeks EU approval for its biosimilar adalimumab candidate, SB5

Industry news / 18 July 2016 / Victoria White, Digital Content Producer

At an estimated $4billion a year, the reference product, Humira, is among the European Union’s largest single drug expenditures…

Infliximab biosimilar Flixabi approved in the EU

Industry news / 31 May 2016 / Victoria White, Digital Content Producer

The EC has granted marketing authorisation in the European Union (EU) for Flixabi, an infliximab biosimilar referencing Remicade…

EC approves Benepali – the first biosimilar of Enbrel

Industry news / 18 January 2016 / Victoria White

Benepali is the first etanercept biosimilar referencing Enbrel to be approved in the EU, making it the first subcutaneous anti-TNF biosimilar available there…

Benepali receives positive opinion from CHMP

Industry news / 20 November 2015 / Victoria White

Previously known as SB4, Benepali (etanercept) is a biosimilar candidate to the reference product Enbrel…

Merck logo

Merck and Samsung Bioepis enter collaboration agreement to develop and commercialize insulin glargine candidate for diabetes

Industry news / 10 February 2014 / Merck

Merck and Samsung Bioepis Co., Ltd., announced that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293…

Biogen Idec logo

Biogen Idec and Samsung Bioepis announce agreement to market anti-TNF biosimilar product candidates in Europe

Industry news / 17 December 2013 / Biogen Idec

Biogen Idec opts-in to commercialization opportunity with joint venture partner…

Biogen Idec logo

Samsung Biologics and Biogen Idec announce formation of biosimilars joint venture Samsung Bioepis

Industry news, News / 27 February 2012 / Biogen Idec

Samsung Biologics & Biogen Idec have established their joint venture…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...